Crystalline forms of valacyclovir hydrochloride
September 6, 2022. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethods and compositions for treating viral infections and guanine acyclic nucleosides Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative Guanine derivative Patent #: 6107302 Inventors
AssigneeApplicationNo. 10236729 filed on 09/06/2002US Classes:544/276Nitrogen attached directly or indirectly to the purine ring system by nonionic bondingExaminersPrimary: Berch, Mark L.Attorney, Agent or FirmForeign Patent References
International ClassesC07D47318A61K 31522 A61K 3152 C07D47300 C07D47300 AbstractProvided are novel polymorphs and pseudopolymorphs of valacyclovir hydrochloride and pharmaceutical compositions containing these. Also provided are methods for making the novel polymorphs and pseudopolymorphs, which include valacyclovir hydrochloride monohydrate and valacyclovir hydrochloride dihydrate.Other References
|
| ||||||||||||||
